Drugs and Vaccines for Developing Countries

Office of Health Economics
Occasional Paper 11/04
Date May 21st 2011

Adrian Towse
Eric Keuffel
Hannah E. Kettler
David B. Ridley

Corresponding author: Adrian Towse

12 Whitehall, London, SW1A 2DY, Tel: 020 7747 8855, E-mail: atowse@ohe.org
About the authors

Adrian Towse is Director of the Office of Health Economics and Visiting Professor at the Department of Economics and Related Studies at the University of York.

Eric Keuffel, PhD is Assistant Professor, Risk, Insurance, and Healthcare Management, at Fox School of Business, Temple University.

Hannah E. Kettler, PhD is Senior Program Officer for Industry Relations, Global Health Office of the President, Bill and Melinda Gates Foundation.

David B. Ridley, PhD is Assistant Professor at The Fuqua School of Business, Duke University.

Acknowledgements

A version of this Occasional paper will be published as a chapter in the Oxford Handbook on the Economics of the Biopharmaceutical Industry, edited by Danzon and Nicholson, to be published 2012.

This Occasional Paper is the work of the authors and does not necessarily represent the views of, respectively, the Office of Health Economics, Temple University, Bill and Melinda Gates Foundation or Duke University.
## Contents

1. Introduction ............................................................................................................... 4
2. Disease Burden ........................................................................................................... 6
3. The economics of securing access to existing and future medicines .................. 9  
   3.1 Increased Pharmaceutical Industry interest in MLICs ....................................... 9  
   3.2 The Role of Patent Protection in MLICs .......................................................... 11  
   3.3 Market Segmentation and Differential pricing .................................................. 12  
       Differential Pricing Policy and Practice ............................................................. 13  
       Intra-Country Differential Pricing .................................................................... 14  
   3.4 Subsidies for the Purchase of Existing Medicines .......................................... 15  
      AMFm - The ACT Subsidy .................................................................................. 16  
   3.5 Donations ......................................................................................................... 17  
4. The economics for securing R&D ......................................................................... 20  
   4.1 R&D Output for Neglected and Very Neglected Diseases ............................... 20  
   4.2 R&D Initiatives and Incentives for MNCs ......................................................... 20  
   4.3 Push and Pull Incentives with Government and Donor Funding ................. 21  
      4.3.1. Push Incentives ....................................................................................... 22  
      Product development partnerships (PDPs) ....................................................... 22  
      Patent Pools ..................................................................................................... 24  
      4.3.2. Pull mechanisms ...................................................................................... 24  
      Advance market commitment .......................................................................... 25  
      Priority review vouchers .................................................................................. 26  
      Patent extensions .............................................................................................. 27  
      Prizes and “de-linking” the cost of R&D and the price of health products ....... 27  
   4.4 Combining, and trading-off between, push and pull mechanisms ............... 28  
5. Conclusions ............................................................................................................. 30  
References ................................................................................................................... 31
1. Introduction

The pharmaceutical industry faces many challenges in addressing the health needs of the poorest in middle and low income countries (MLICs). The economic issues related to pharmaceuticals for these patients differ depending on whether the medicine treats a “global disease” (a therapeutic category which has a substantial existing market in high-income countries) or a “neglected disease” (one which largely afflicts only those in low-income countries)\(^1\). In the case of the former, medicines widely available in richer countries are often unavailable or unaffordable in poorer countries for a variety of reasons including: an inability to afford to buy out-of-pocket; limited health insurance; poor delivery infrastructure; fiscally restricted governments; and weak regulatory and governance capacity. In the case of “neglected diseases”, subsidies and policies to mitigate risk are required to motivate for-profit companies to develop effective medicines and even then, the resulting products may not be affordable.

A lot has changed over the past decade. Multinational companies (MNCs) in partnership with academia, not-for-profits, governments and foundations have increased funding and effort to develop new technologies for HIV/AIDS, TB, malaria, and some other tropical diseases (Policy Cures, 2011). Local drug and vaccine companies in emerging markets, such as India, China and Brazil, are also investing resources in innovative solutions for neglected diseases as they try to evolve from low cost generic product suppliers into R&D based companies (Frew et al., 2008). Government and philanthropic funding to assist low-income countries with procurement of some “global” medicines and vaccines has increased these products’ availability for poor populations. In addition, the growth in GDP per capita, expansion of the middle class and, in some emerging market countries, the extension of health insurance has motivated profit-seeking manufacturers to view some MLICs as an important source of future revenue growth. Many are exploring innovative marketing and pricing strategies in an attempt to expand sales and increase availability, including differential pricing where the lowest income groups secured the lowest price for drugs and vaccines.

The strategic philosophy of some of the MNC leaders is also starting to change. There is increased recognition that they need to make a substantive contribution to global health. And to make those contributions sustainable, they require approaches that are both commercially viable and socially credible. Some groups like the Access to Medicines Foundation, based in the Netherlands, are actively monitoring what companies are doing, ranking performance against best practice (Access to Medicines, 2010). Arguably this instrument, which uses a transparent challengeable mechanism, serves both companies and their critics as they work to solve the health problems of the poorest.

\(^1\) The WHO organizes diseases into three categories – global, neglected and very neglected. We discuss all three in Section 2 but have grouped Type II and III together for the purpose of this summary.
In this paper we set out the context for the problem of insufficient affordable medicines to address health issues in developing countries. We also highlight some of the drivers of recent positive trends. We then detail policies and proposals intended to increase access to global medicines (those with a developed country market) by lowering prices, including: differential pricing; compulsory licensing; and donations. Finally, we consider policies aimed at encouraging the development of new medicines for neglected diseases (prevalent only in lower income countries) by reducing company born costs and risks and/or expanding the expected revenue for the manufacturer by increasing product demand. In particular, we describe “push” mechanisms that subsidize research inputs, and “pull” mechanisms that reward research output.

Some critics of subsidizing drug procurement and R&D contend that more cost-effective means of improving health status in developing nations may be through low tech, low cost health measures (e.g. mosquito bed nets, improved water supply) and non-health policy measures (reduction of developed country farm subsidies, investment in education) (Attaran, 2004). Without denying a role for these other tools and policies, the evidence suggests that medicines must be part of the solution as well. Several recent analyses stress the health burden due to high priority diseases (both infectious and communicable) for which medicines and vaccines serve as cost-effective treatments (CMH, 2001; DCPP2, 2006; Barninghausen et al., 2008; Jamison et al., 2009) with one study concluding that subsidizing R&D to neglected diseases was likely to be a cost-effective way of achieving health gain (Gray et al., 2006).

While this paper will focus on R&D effort and affordability issues primarily related to ex-manufacturer\(^2\) drug prices, access to medicines also requires improving healthcare infrastructure to ensure that safe and effective products physically get to patients without mark ups that prohibit access (CGD, 2007; Levine, Pickett et al., 2008).\(^3\) Alongside the developments in product development and introduction, donors and global health agencies have placed more attention on the critical role that regulators, retailers, distributors and wholesalers have on product quality, availability and price. New funding for products combined with weak regulatory systems and weak information systems can contribute to a high level of counterfeit medicines in developing countries. WHO analyses suggest that the global share of counterfeit medicines is roughly 10%, but may be upwards of 40% in some developing countries (WHO-IMPACT, 2006; Rollings, 2007). These and other supply chain quality risks contribute to multinational pharmaceutical manufacturer reticence to participate in these markets (Levine, 2007; Yadav et al., 2007; Dalberg, 2008).

---

\(^2\) Ex-manufacturer drug prices are prices prior to any wholesaler, retailer and tax mark ups.

\(^3\) Many therapies require administration and oversight by health care personnel, in order to mitigate the build up of drug resistance, others require a network (especially of refrigeration) to maintain product quality.
2. Disease Burden

The World Health Organization disease classification divides diseases into three broad categories on the basis of global burden and share of burden concentrated in the developing world (CMH, 2001; WHO, 2006) as illustrated in Figure 1:

- **Type I** “global” diseases appear on the right side of Figure 1 and include cardiovascular disease, diabetes, cancer and other disease categories prevalent in both rich and poor countries (Reddy, 2004; Greenberg, Raymond et al., 2005; Yach et al., 2006). The size of the expected markets creates necessary incentives to companies to invest in the development of new treatments but price often prohibits uptake in developing countries. Evidence that research responds primarily to demand in developed countries, particularly demand in patent-protected developed countries, was found by Kyle and McGahan (2008) using evidence on drug development changes after the 1994 Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). Research effort is less sensitive to demand in developing countries, regardless of whether those countries have patent protection (Kyle, 2008).

- **Type II** diseases, which appear in the middle and left side of Figure 1, are “neglected diseases”. Those on the top of Figure 1, such as HIV/AIDS, tuberculosis and malaria, impart the largest burdens in terms of morbidity and mortality and while they may be present in both rich and poor countries, burden is disproportionately concentrated in the poorest countries. There has been some R&D over the past two decades in Type II diseases, but funding and effort has been concentrated in HIV. Furthermore, to the extent companies perceive an incentive to fund R&D, they tend to concentrate on product formulations and profiles that reflect the needs of patients and health systems of the developed rather than the developing countries. For example, health impact in developing countries depends upon product variations such as shorter treatment regimens, pediatric as well as adult formulations, point of care diagnostics and a focus on prevention relative to treatment but from the companies’ perspective, this is not where the money currently is.

- **Type III** diseases, appearing on the far left of Figure 1, are referred to as the “very neglected diseases,” they appear overwhelmingly or exclusively in developing countries and are the least commercially attractive (and thus, historically, have received the least R&D funding). This category includes tropical parasitic diseases such as leishmaniasis, schistosomiasis, and trypanosomiasis, and intestinal nematode infections such as ascariasis, trichuriasis, and hookworm. Diarrheal diseases are also included here. Despite a disease burden that exceeds that of malaria, R&D funding for diarrheal diseases is less than one third of R&D funding for malaria (Table 1).
Figure 1

Disease Burden: Disability-adjusted life years lost in low- and lower-middle-income countries relative to the rest of the world
### Table 1
#### Research and Development Funding by Disease in 2007, 2008 and 2009 in Nominal Dollars

<table>
<thead>
<tr>
<th>2009 Rank</th>
<th>Disease</th>
<th>FY2007 R&amp;D US$ (000)</th>
<th>FY2008 R&amp;D US$ (000)</th>
<th>FY2009 R&amp;D US$ (000)</th>
<th>2007%</th>
<th>2008%</th>
<th>2009%</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>HIV/AIDS</td>
<td>$1,083,018</td>
<td>$1,215,842</td>
<td>$1,168,029</td>
<td>42.3</td>
<td>39.4</td>
<td>35.7</td>
</tr>
<tr>
<td>2</td>
<td>Malaria</td>
<td>$468,449</td>
<td>$565,986</td>
<td>$602,396</td>
<td>18.3</td>
<td>18.3</td>
<td>18.6</td>
</tr>
<tr>
<td>3</td>
<td>Tuberculosis</td>
<td>$410,429</td>
<td>$467,539</td>
<td>$579,139</td>
<td>16</td>
<td>15.1</td>
<td>17.6</td>
</tr>
<tr>
<td>4</td>
<td>Diarrhoeal Diseases</td>
<td>$113,889</td>
<td>$138,160</td>
<td>$184,975</td>
<td>4.4</td>
<td>4.5</td>
<td>5.7</td>
</tr>
<tr>
<td>5</td>
<td>Dengue</td>
<td>$82,014</td>
<td>$132,471</td>
<td>$171,340</td>
<td>3.2</td>
<td>4.3</td>
<td>5.2</td>
</tr>
<tr>
<td>6</td>
<td>Kinetoplastids</td>
<td>$125,123</td>
<td>$145,677</td>
<td>$164,258</td>
<td>4.9</td>
<td>4.7</td>
<td>5.1</td>
</tr>
<tr>
<td>7</td>
<td>Helminths (Worms and Flukes)</td>
<td>$51,592</td>
<td>$69,518</td>
<td>$81,403</td>
<td>2</td>
<td>2.3</td>
<td>2.5</td>
</tr>
<tr>
<td>8</td>
<td>Bacterial Pneumonia and Meningitis</td>
<td>$32,517</td>
<td>$32,517</td>
<td>$69,616</td>
<td>1.3</td>
<td>3.1</td>
<td>2.2</td>
</tr>
<tr>
<td>9</td>
<td>Salmonella Infections</td>
<td>$9,117</td>
<td>$41,079</td>
<td>$40,292</td>
<td>0.4</td>
<td>1.3</td>
<td>1.2</td>
</tr>
<tr>
<td>10</td>
<td>Leprosy</td>
<td>$5,619</td>
<td>$10,073</td>
<td>$10,988</td>
<td>0.2</td>
<td>0.3</td>
<td>0.3</td>
</tr>
<tr>
<td>11</td>
<td>Rheumatic Fever</td>
<td>$1,670</td>
<td>$2,268</td>
<td>$3,084</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>12</td>
<td>Trachoma</td>
<td>$1,680</td>
<td>$2,225</td>
<td>$1,841</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>13</td>
<td>Buruli Ulcer</td>
<td>$2,413</td>
<td>$2,140</td>
<td>$1,879</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>14</td>
<td>Platform Technologies</td>
<td>$9,997</td>
<td>$16,570</td>
<td>$22,802</td>
<td>0.4</td>
<td>0.6</td>
<td>0.7</td>
</tr>
<tr>
<td>15</td>
<td>Core Funding</td>
<td>$110,922</td>
<td>$110,403</td>
<td>$74,381</td>
<td>4.3</td>
<td>3.4</td>
<td>2.3</td>
</tr>
<tr>
<td>16</td>
<td>Unspecified</td>
<td>$51,619</td>
<td>$78,180</td>
<td>$88,144</td>
<td>2</td>
<td>2.5</td>
<td>2.7</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td><strong>$2,560,069</strong></td>
<td><strong>$3,094,202</strong></td>
<td><strong>$3,304,862</strong></td>
<td>100</td>
<td>100</td>
<td>100</td>
</tr>
</tbody>
</table>

*Source: Policy Cures (2010)*
3. The economics of securing access to existing and future medicines

We turn initially to economic developments and policy issues most pertinent for Type I diseases and some Type II diseases like HIV and pneumonia, where products exist and are available in developed and some high-middle income countries but are often not available and/or not affordable in low-middle and low income countries. For the rest of Type II and Type III diseases, public and philanthropic funders and policy makers have opportunities through their support of product development, to influence the design and price of the product before it gets to market. But once approved, they have less opportunity to use the companies’ developed world markets as a lever to negotiate better access for the poorest and need to rely either on company philanthropy in the form of donations or donor supported procurement to address any remaining affordability issues.

3.1 Increased Pharmaceutical Industry interest in MLICs

While the diseases of the poor are a low priority, many MNCs are looking to expand in MLIC markets to grow the sales of their products. Sales to Asian, African, and Australian markets doubled between 2004 and 2009 and Latin America experienced similarly robust growth (Figure 2). Pharmaceutical manufacturers are cutting jobs in developed countries and adding jobs in emerging markets (Loftus, 2010; Goldstein 2009). In some cases, as in India, the companies are looking to tap into the recent growth in income levels that will likely translate into more out-of-pocket spending on pharmaceuticals as well as other health products. In other MLICs, economic growth is coupled with the expansion of state run insurance programs (as in China via new rural and urban worker and resident social health insurance programmes) (Zhou, Yang et al., 2008; Wagstaff, Lindelow et al., 2009; Cavanagh, 2010).

A number of factors have bolstered company interest in the emerging markets above and beyond rapid growth rates of per capita income. This list includes but is not limited to: improving macroeconomic stability; stronger IP protection thanks to patent and trade reforms through TRIPs and individual country trade agreements; improvements in healthcare delivery systems; and the pressure of expiring patents in developed markets, forcing companies to seek new opportunities (Riahi, 2002; Sehgal, 2002; Vilela, 2002; BMI, 2010; Cavanagh, 2010).

Multinationals are increasing their presence in emerging markets via acquisition, joint ventures, alliances and venture capital participation with local companies (BMI, 2010; Cavanagh, 2010). Table 2 highlights some recent activity in India. However, they are still struggling to identify appropriate business models for MLICs given that most of the population often have limited access to third party payer led insurance and are not able to pay high prices out-of-pocket. Success will likely require a shift from the companies’ traditional model of supplying small volumes at high prices to the high income part of the population. As we show below, tools and models
companies and partners are developing to address access issues for the poorest may prove to be important training opportunity for companies as they think about broader expansion in MLICs.

Small and medium local companies are also growing in MLIC countries, notably India, China, Cuba, South Africa, and Brazil. In some cases, these companies are developing products for neglected diseases (Frew, Liu et al., 2009). Successful models for companies in developing countries include the generics industry, in which Indian companies have become major global players by serving developed and developing country markets, and the global vaccines industry, in which Asian companies have also emerged as suppliers for global and regional contracts with international agencies.

Niche companies might benefit from facilitation by an independent organization which provides business support, access to venture capital, advocacy for funding, and networking (Frew, Liu et al., 2009). BIO Ventures for Global Health offers a similar service to help companies based in developed markets. While successful developing country manufacturers primarily compete in the commercial market locally and abroad, large subsidization programs (e.g. GAVI) have also served as important customers, in particular for Indian vaccine manufacturers.

Figure 2

Distribution of pharmaceutical sales across regions and over time (US$ Billions at constant exchange rates)

Source: IMS Health
**Table 2**

Select Acquisitions and Alliances in India

<table>
<thead>
<tr>
<th>MNC</th>
<th>Seller or Partner</th>
<th>Deal Size / Type</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott</td>
<td>Piramal Healthcare</td>
<td>$3.7 B. / Acquisition</td>
<td>June 2010</td>
</tr>
<tr>
<td>Daiichi Sankyo</td>
<td>Ranbaxy (34%)</td>
<td>$2.4 B./ Acquisition</td>
<td>June 2008</td>
</tr>
<tr>
<td>Mylan Labs</td>
<td>Matrix Labs (71.5%)</td>
<td>$736 M./ Acquisition</td>
<td>August 2008</td>
</tr>
<tr>
<td>Sanofi Aventis</td>
<td>Shantha Biotech</td>
<td>€550 M / Acquisition</td>
<td>July 2009</td>
</tr>
<tr>
<td>Fresnius SE</td>
<td>Dabur Pharma (73.3%)</td>
<td>$185 M. / Acquisition</td>
<td>April 2008</td>
</tr>
<tr>
<td>GSK</td>
<td>Dr. Reddy’s</td>
<td>Alliance</td>
<td>July 2009</td>
</tr>
<tr>
<td>Pfizer</td>
<td>Aurobindo</td>
<td>Alliance</td>
<td>March 2009</td>
</tr>
</tbody>
</table>

3.2 The Role of Patent Protection in MLICs

For a number of economic and policy reasons, MLIC countries have historically limited the protections for IP. A divergence of economic interest between MLICs and MNCs was recognized in the WTO TRIPS (Trade Related Aspects of Intellectual Property Rights) agreement which made drug patent recognition a condition of membership of the WTO for all countries, including MLICs, with three provisos:

- only products patented after 2005 were covered, with existing medicines “grandfathered” into the new systems;
- the least developed nations were given an exemption from introducing patents until 2016;
- all countries (rich and poor) are allowed to use compulsory licensing in the circumstances of a “public health emergency.”

In addition the Treaty permits individual countries to choose their own policies on international exhaustion (which prohibits parallel trade or resale of pharmaceuticals outside the original country market). It is therefore possible for high-income countries to prohibit parallel trade and many do. It is, however, also possible for countries receiving low prices to ban parallel exports, thus protecting themselves from losing the benefit of these low prices.

Critics argued that the TRIPS provisions would not be enough to prevent price increases once countries became TRIPS compliant (Lanjouw, 1998; Watal, 2000; Fink, 2001). These arguments make assumptions about patented drug prices and the price impact of generic competition, both of which we consider below. In countries such as India, the pre-TRIPS IP policies combined with other industry policies helped enable the development of an industry of companies that sold generic versions of medicines that were still on patent in developed countries. Arguably these
companies are now competing in global generic markets and some are trying to move upstream into the business of developing new products.

3.3 Market Segmentation and Differential pricing

The considerable R&D investment required to bring a pharmaceutical product to market (DiMasi et al. 2003) is a sunk (and therefore fixed) cost which firms expect to recover. One solution to this fixed cost problem is Ramsey pricing (also known as “differential pricing” and “tiered pricing”) whereby prices are kept low for low income market segments with high demand elasticity, and high prices designed to recover R&D costs are charged to high income market segments with lower demand elasticity (Danzon and Towse, 2003).

In theory, when there are significant disparities of income, differential pricing can therefore both increase returns to R&D (so stimulating more research) and expand overall access to medicines, particularly to lower income groups of patients or low income countries (Danzon and Towse, 2003). To do this, prices in relatively richer countries would exceed the marginal cost of production and distribution by enough, in aggregate, to cover the fixed costs of research and development while prices in lower-income countries would be set close to marginal costs. Table 3 indicates the nature of income differentials across countries.

**Table 3**
GNP per Capita, Spending and Health Outcomes (by Income Classification)

<table>
<thead>
<tr>
<th>Development Category</th>
<th>Population (Millions)</th>
<th>Mean Annual GDP per capita ($US)</th>
<th>Total Annual Spending on Health* ($US)</th>
<th>Life Expectancy (years)</th>
<th>Infant Mortality (per 1000 live births)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low Income Countries</td>
<td>956</td>
<td>$486</td>
<td>$27</td>
<td>59</td>
<td>77</td>
</tr>
<tr>
<td>Lower-Middle Income Countries</td>
<td>3,661</td>
<td>$1,879</td>
<td>$81</td>
<td>68</td>
<td>47</td>
</tr>
<tr>
<td>Upper-Middle Income Countries</td>
<td>941</td>
<td>$7,555</td>
<td>$488</td>
<td>71</td>
<td>20</td>
</tr>
<tr>
<td>High Income Countries</td>
<td>1,061</td>
<td>$38,327</td>
<td>$4,406</td>
<td>80</td>
<td>6</td>
</tr>
</tbody>
</table>

*Components include public domestic spending, private domestic spending and donor assistance.
Source: World Bank (World Development Indicators)
This approach is only viable if markets remain segmented, i.e. there is no significant leakage of prices, through the use of international reference pricing (whereby payers in high income countries set their prices by reference to the (lower) prices paid in low income countries) or the movement of physical product (parallel trade) from low price markets to high price markets, undermining the higher prices in these markets (Danzon, 1998; Kyle, 2008).

One way to avoid “leakage” through price referencing is the use of confidential discounts (Danzon and Towse, 2003). Confidential discounts are the chief means through which U.S. managed-care purchasers negotiate lower prices. Discounts to low-income countries or market segments could be given as confidential rebates paid directly to the ultimate purchaser. Wholesalers are supplied at a common price or act as distribution agents who do not own the product. Confidentiality could eliminate the opportunity for other purchasers to demand similar rebates and prevent wholesalers or other parallel traders purchasing the product at the low price intended for low-income countries and then exporting it to higher-price countries. It could also prevent arbitrage between market segments within countries.

Transparency facilitates price comparisons and so undermines differential pricing (Kyle and Ridley, 2007). However, advocates for transparency contend that bulk negotiation and knowledge of transaction prices elsewhere will enable reduced prices to be negotiated more generally, promoting access and so increasing static efficiency and hence consumer welfare (albeit with some offsetting reductions in producer welfare). The World Health Organization (WHO) and Health Action International (HAI) are working to post international pharmaceutical price comparisons at different levels of the supply chain (ex-manufacturer, wholesale, retail) (Babar, Ibrahim et al., 2007; Cameron, Ewen et al., 2009). The key difference between advocates of transparency and of confidentiality is their view of the impact on incentives for R&D. The focus of those advocating transparency is short term (static) efficiency. If companies cannot, as a consequence, earn returns on R&D then they would argue that other mechanisms will be needed to incentivize or undertake R&D.

### Differential Pricing Policy and Practice

Starting in the late 1990s, non-governmental organizations (NGOs), notably Médecins Sans Frontières and Oxfam, combined with HIV/AIDS activist groups, the World Health Organization, the Clinton Foundation and governments such as the U.K. Department for International Development stepped up the pressure on companies to bring the prices of ARVs down for the poorest countries. Many companies responded by introducing a differential pricing system with discounts for the poorest countries. Companies have also employed technology transfer where they provide voluntary licenses to generics manufacturers in the expectation that these manufacturers will supply products at low prices.
In addition to HIV/AIDS, forms of differential pricing have been employed for contraceptives and vaccines (Yadav, 2010). NGOs continue to call for transparency so as to monitor how systematic the price differentiation is (Oxfam, 2007). Advocates of confidentiality counter that transparency limits pricing freedom and potentially restricts access to medicines. The motivation for companies to employ discounts will decline sharply if all the details about those discounts are made public and then used as a reference for other buyers outside the lowest tiers. There are other tools to bring prices for new medicines down – the allowance for competition pre-patent expiry – but at the risk of long term investments in new R&D.

**Intra-Country Differential Pricing**

It is even more challenging to use differential prices within countries than between countries. Within-country market segmentation is more feasible if there are different healthcare purchasers acting on behalf of the income groups identified, or if these groups attend different healthcare facilities to receive their medicines. If, for example, public-sector payers targeting lower income groups can be distinguished from private-sector payers targeting higher income groups, differential pricing is more likely to evolve. While the potential value for revenue, access and even profit associated with intra-country differential pricing is increasingly recognized – the mechanisms available to enforce differential pricing to date are limited and uncertain (BVGH, 2008; PF3, 2009).

A variety of approaches have been attempted to segment markets within countries and provide differential pricing as indicated in Table 4. Differential pricing within countries appears more viable when: (1) pharmaceutical companies deal with large purchasers rather than with individuals (although individual discount cards have been used with some success; (2) uniform list prices are posted with confidential discounts from the list price paid separately to purchasers; and (3) lower prices can be passed on to patients in self-pay or co-pay markets, rather than be captured by intermediaries.

**Table 4**

**Price Discrimination Mechanisms in Developing Countries**

<table>
<thead>
<tr>
<th>Level of Price Discrimination</th>
<th>Characterization / Example</th>
<th>Advantages / Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individual</td>
<td>Novartis Gleevec “GIPAP” program offers full contribution, shared contribution (local governments, other payers share cost) and copay (individual shares cost) models depending on the geography and ability to pay of the patient.</td>
<td>Targeted subsidies (+)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>High transaction costs (-)</td>
</tr>
<tr>
<td>Institutional or Delivery</td>
<td>Price may differ depending on whether payer is the public or private sector. Channels such as NGO clinic or specialized hospitals which attracts either wealthy or poor</td>
<td>Potential to distribute on a relatively large scale (+)</td>
</tr>
<tr>
<td>Channel</td>
<td></td>
<td>Monitoring costs to avoid arbitrage(-)</td>
</tr>
</tbody>
</table>
### 3.4 Subsidies for the Purchase of Existing Medicines

Governments, foundations and multilateral institutions have rapidly increased funding over the last decade to support health in low- and middle-income nations. Between 2001 and 2008 health Official Development Assistance (ODA) from the G20 and multilaterals increased approximately by a factor of 2.5 from $7.6 billion to $26.4 billion (Kates et al., 2010). Some of this share has been directed toward programs which purchase medicines such as the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR)\(^5\), the US President’s Malaria Initiative (PMI), the Global Fund to

\(^4\) An important consideration related to subsidization is which diseases or countries deserve special consideration either with regard to support for R&D or for programs which expand access. We discuss the basis for choice of diseases in the next section of the paper. In the GAVI case, in terms of countries, if donors decide to stick to the $1000 per capita ceiling for entitlement (or indeed to reduce it in the face of limited funds) then rapidly growing economies like China and India will no longer be eligible for donor subsidies and greater engagement by their own governments will be required to meet the health needs of their poor populations.

\(^5\) PEPFAR, the cornerstone of the US President’s Global Health Initiative (GHI) (initially $63 billion over 6 years and then reauthorized with an additional $48 billion in 2009 out to 2014), accounts for approximately three-quarters of the GHI (Kates, 2010). Purchase of medicines is one piece of a much broader set of PEPFAR program objectives; in 2009, PEPFAR spent $425 million on ARVs out of a budget above $6 billion (PEPFAR, 2010).
Programs such as the Affordable Medicines Facility for Malaria (AMFm) (discussed in the next section) and the Advanced Market Commitment for pneumococcal vaccines (AMC), (discussed in Section 4), indicate that it is possible for funders to employ strategic subsidies to bring down price and increase supply. That said, the impact of the financial crisis since 2008 combined with the introduction of new, more expensive vaccines for rotavirus, HPV and pneumococcal disease, is seriously challenging the GAVI (and UNITAID and GFATM) model. The demand for funds is growing at the time when the supply of aid funds from donors declines.

**AMFm - The ACT Subsidy**

One novel subsidization effort proposed by economist Kenneth Arrow, the Affordable Medicines Facility-Malaria (AMFm), uses a subsidy to the manufacturer of artemisinin combination therapies (ACTs) to reduce them towards the relatively cheaper price of the less effective mono-therapies and thereby attempt to slow the rise of resistance to artemisinin. Through the AMFm the ACT is supplied through existing distribution systems (both public and private) (Arrow, Panosian et al., 2004; Laxminarayan, Over et al., 2006; Laxminarayan and Gelband, 2009; Laxminarayan, Parry et al., 2010).

A manufacturer targeted instrument works only to the extent that the manufacturer controls the final price or that the distribution system is sufficiently competitive such that mark-ups do not undo the impact of the subsidy. Research to date in developing country settings is mixed, but generally confirms that concentration among distributors, wholesalers and/or retailers and prices (or mark-ups) are positively correlated (Goodman, Kachur et al., 2009; Patouillard, Hanson et al., 2010). However, in this case of ATCs, patients cannot tell the difference between monotherapy and combination therapy in terms of benefit to them and so there is no medical basis for retailers to mark up the ACT relative to the monotherapy if both products are supplied to them at comparable prices. According to a pilot study in

---

6 For example, the share of expenditures directed toward generics in the PEPFAR program has shifted from 9% in 2005 to 76% in 2008 (Holmes, Coggin et al., 2010)
Tanzania, the subsidy at the top of the private sector supply chain can significantly increase usage of ACTs and reduce their retail price at the level of common monotherapies. In the study, people in the districts where the subsidy was introduced increased their use of ACTs from 1% to 44% in one year (Sabot, Mwita et al., 2009).

3.5 Donations

Donations of product are another tool that companies can and do employ to improve product access. The International Federation for Pharmaceutical Manufacturers Association (IFPMA) provides an up to date database of company donation programs to developing countries. One of the first is Merck’s donation of Mectizan (ivermectin) for the treatment of worms. Originally developed for the veterinary market (worms in dogs and cats), Merck partnered with TDR of the WHO to develop a version for humans and began donating it to Africa first for the treatment of onchocerciasis (River Blindness) in 1987, and from 1998, also for lymphatic filariasis. As of 2010, more than 700 million people had been treated with ivermectin (IFPMA, 2010). In Africa and Yemen, ivermectin is co-administered with albendazole, donated by GSK. The donation and distribution of these therapies involves a global public-private partnership of United Nations agencies, governmental and nongovernmental organizations, local communities, and the private sector. In October 2010, at the launch of WHO’s First Report on Neglected Tropical Diseases, a number of companies including GSK, Eisai, J&J, Sanofi-Aventis and Novartis announced increased commitments to their current donation programs.

Critics of donation programs have two concerns. Firstly, donation programs are only good as long as the company involved is willing to continue donating the product and therefore are not necessarily a sustainable solution to the problem – be that of supply or affordability or both. Secondly, donating could, in theory at least, crowd-out generic competitors who cannot compete with “free” (Oxfam, 2007). Donation programs need to have a long term strategy for sustainability, so that the immediate benefits are not offset by any later disruption to supply.

3.6 Flexibility in patent rules to improve access

A number of NGOs and academics have made proposals and advocated that governments use stronger IP rules and tools to secure access to medicines for the poorest. Three are provided below. All three have in common the fundamental premise that companies should forgo patent rights in select poor countries to promote access. They assume that innovators’ incentives to develop new therapies are minimally impacted by their ability to patent in the poorest countries and that
generic companies would enter these poor markets with adequate quality generic copies as soon as the patents are no longer enforced.

(1) The country is poor and the product is deemed “essential”. Médecins Sans Frontières (MSF 2008) and others have advocated the countries make better and more frequent use of the compulsory license TRIPs provision that allows governments to ignore patent rights when there is a national health emergency 7. Such national emergencies might include public health crises, including those relating to HIV/AIDS, tuberculosis, malaria, and other epidemics;

(2) The country is poor and there is a lucrative market elsewhere. Lanjouw (2006) proposed that developers have patent rights either in rich countries or in poor countries, but not in both. Developers selling in rich countries would agree not to enforce patent rights in poor countries (countries that constitute two percent or less of global sales value). In those poor countries, other companies could manufacture and sell generics without licenses. In the remaining countries, normal TRIPS rules would apply. It would have an impact, for example, on hypertension, where a large number of poor countries would constitute only two percent of sales, but not for malaria, however, where much of the global sales are in poor countries.

(3) The international community “buys out” the patent. Manufacturers could give up patent rights in return for fair compensation from governments. This is linked conceptually to recent proposals for prizes, which we discuss below. Participation in a patent buyout could be required or voluntary (Kremer, 1998). Banerjee, Hollis et al. (2010) propose that manufacturers that set prices equal to manufacturing costs could receive cash from a Health Impact Fund for up to 10 years. The share of the fund paid to a given manufacturer would depend on the net health impact of the product. The fund would be created by contributions from governments and foundations. The amount of funding for a given drug would not be specified in advance but would depend on use of the drug and evidence of realized benefits. The lack of specificity would provide flexibility in adapting to new innovations and needs. It would, however, concern manufacturers by introducing the possibility of opportunistic behaviour on the part of the Fund’s administrators (DiMasi and Grabowski, 2004).

3.7. Increasing Generic Competition

In most MLICs generics versions of originator drugs are available. Whether drug prices are affordable in MLICs in part depends on the prices of generics. There is often an implicit assumption that generics are always low price. Empirical work by Danzon, Mulcahy and Towe (2011) analyzing determinants of ex-manufacturer prices for originator and generic drugs to treat HIV/AIDS, TB and malaria in MLICs found that although there were multiple originator and generic competitors in most

---

7 Although in this case the government might agree to pay a royalty fee for the patent owner.
MLIC country/classes, competition from generics was not effective at reducing prices in self-pay retail pharmacy channels. Because generics are not required by regulation to meet high quality standards, quality uncertainty led to branded generics that compete on brand name rather than price.

They found, however, that pooled procurement mechanisms achieved significantly lower originator and generic prices. For originators, this may reflect greater willingness to grant discounts to a distribution channel that reduces risks of price spillovers to richer purchasers in the same country and to other countries. For generics, procurement attracted multinational generic suppliers that meet quality standards, and have scale advantages over the local branded generics that dominate the retail pharmacy channels.

Empirical evidence suggests that better mechanisms are needed to promote price competition and enable differential pricing between and within low and middle income countries and that third party procurement or the use of other protected channels may offer a route forward.
4. The economics for securing R&D

4.1 R&D Output for Neglected and Very Neglected Diseases

Insufficient demand (too little spent on health care and pharmaceutical in particular by patients in developing countries) combined with high scientific and process (regulatory systems, trial sites) risks and costs has explained the dearth of public and private R&D spending for Type II and III diseases (Table 5) (Frick et al., 2001; Shah, 2002; Onwujekwe, Hanson et al., 2004; Weiner, 2002; Dolgin, 2010). Simply stated, product development was not commercially viable despite the significant health burden associated with these diseases.

The low absolute levels of R&D and new products for these diseases are well documented. Pecoul et al. (1999) found 13 of 1450 NCEs developed between 1972 and 1997 directed toward neglected diseases. Trouiller et al. (2002) reported that from 1975-1999 just 16 of 1393 new chemical entities (NCEs) were registered for tropical diseases or tuberculosis. Many of these products came out of research intended for oncology or veterinary markets (Ridley, 2003), all received public support and many were developed in partnership with the WHO’s TDR (Special Programme for Research and Training in Tropical Diseases) (Trouilliller et al., 2002; Ridley, 2003).

Evidence suggests that in the period since 2000, and the establishment of product development partnerships, the amount of public, private, funding and the number of products has increased. The annual rate of new product approvals for neglected diseases and very neglected diseases grew from 1.8 in 1975-1999 to 2.6 in 2000-2009 (Cohen, 2009). Between 2000-2009, 26 drugs and vaccines for neglected and very neglected diseases received worldwide marketing approval (Cohen 2009). Research output remains low, however, relative to disease burden and relative to Type I diseases.

4.2 R&D Initiatives and Incentives for MNCs

The question as to whether companies and their investors are simply “missing” a profitable opportunity because of the lack of good information about the neglected disease markets has prompted a number of organizations to try and generate market assessments, especially for Type II diseases prevalent in middle as well as low income countries like TB and Pneumococcal vaccine (GATBD, 2001, BVGH, 2006). While methodologies vary considerably, the TB drug and vaccine studies indicate close to $500m per annum markets but also sizeable regulatory, political and logistical challenges to securing these markets.

---

8 For the purposes of analysis, “tropical diseases” included parasitic disease (malaria, African trypanosomiasis, Chagas’ disease, schistosomiasis, leishmaniasis, lymphatic filariasis, onchocerciasis, and intestinal nematode infections), leprosy, dengue, Japanese encephalitis, trachoma, and infectious diarrhoeal disease.
Multinational companies are committing more resources towards neglected disease R&D including the establishment of dedicated research facilities (GSK’s Tres Cantos, Spain, Novartis’ Institute for Tropical Disease in Singapore and Vaccine Institute for Global Health in Sienna, Italy, Astra Zeneca’s TB Facility in Bangalore, India, Merck’s Hilleman Research Lab (in partnership with the Wellcome Trust) in India) but relatively little of the cost of these projects is funded out of the companies’ commercial budgets. External funds and partnerships play a critical role in funding and supporting these initiatives.

Global health funders can leverage and magnify the commercial value of these opportunities through the design of incentives and funding initiatives. Companies will require funding support to take the decision to work on Type II and III diseases but how much and in what form varies by disease and by company. In theory, the greater the actual market, the lower the required public or philanthropic subsidy.

4.3 Push and Pull Incentives with Government and Donor Funding

Several organizations and researchers have examined mechanisms for funding and prioritization of R&D (CMH, 2001; GFHR, 2002; Towse and Kettler, 2005a; Hecht, Wilson et al., 2009; WHO, 2010). Appropriate subsidies for these neglected diseases ideally correct for the lack of incentives that the small markets create by tipping the risk return ratio in favor of new research, development and delivery (Zeckhauser 2002). Jena, Mechoulan, and Philipson (2011) estimated that the "private market provides insufficient spending for research and development, possibly under-providing R&D by as much as 60 percent if one accounts for the benefits of altruism."

Mechanisms designed to encourage companies to undertake R&D on neglected diseases are generally characterized as either “push” programs which support inputs into research or “pull” programs which pay for outcomes or outputs of research (Kettler, 2000; Kremer, 2002; BVGH, 2009; Hecht, Wilson et al., 2009). In terms of simple economics, push mechanisms shift the supply curve down by reducing the cost of R&D through direct grants, technical assistance or tax breaks. Pull mechanisms shift the demand curve up and out by rewarding successful product development with higher prices and/or more volume. Push mechanisms include direct grants for R&D (e.g. from the US NIH), tax credits for R&D and fast-track approval for the neglected disease product (i.e. time saving measures). Pull mechanisms include purchase commitments, tax credits for sales of developed products for high priority indications, market exclusivity rights, patent extension rights transferable to other medicines, priority review vouchers (where companies are rewarded for their neglected disease efforts with a priority review for another product of their choosing), research tournaments, prizes and signaling via reimbursement for related products (Kettler, 2000; Kremer, 2002; WHO, 2008).

A key distinction between push and pull is whether the reward is conditional on successful product development. Pull funding is contingent on success. Push funding reduces the cost or risk to the product developer but is not contingent on success.
4.3.1. Push Incentives

Product development partnerships (PDPs)

The dominant push mechanism in global health is the product development partnership (PDP) where donors fund the initiative and the initiative, in turn, evaluates, funds, helps manage and support projects underway in research institutes, universities, companies or some combination. While the structure of the contract varies, the PDP tends to fund the product developer on a stage by stage basis with each partner retaining the option to drop out at the end of any stage. In exchange for the funds, the product developer agrees to global access agreements to help ensure that any successful product that results from their partnership reaches the intended patients. The access agreements speak to price as well as supply commitments. Donors carry most of the risk of failures because they pay up-front rather than upon receipt of the product. And as was noted above, how much needs to be donor funded will depend on the company, product and disease. A diagnostic company may seek less research support to work in TB but still require/look to the PDP to provide technical assistance and marketing support. An emerging vaccine company may require funding and technical support to complete product development but find the market sufficient to invest their own resources in manufacturing and distribution.

Many PDPs emerged during the late 1990s / early 2000s and typically consist of a non-profit organization or “virtual” company that partners with industry, governments, funders and other organizations to develop a portfolio of medicines, vaccines or products for use in the treatment of neglected diseases (Kettler and Towse, 2002; GFHR 2008). By one count, there are as many as 24 PDPs (GFHR 2008). These include the Medicines for Malaria Venture (MMV), International AIDS Vaccine Initiative (IAVI), World Health Organization: Special Programme for Research and Training in Tropical Diseases (WHO/TDR), Institute for One World Health (iOWH), Drugs for Neglected Diseases initiative (DNDi) and the Infectious Disease Research Institute (IDRI). Leading donors for PDPs include the Bill and Melinda Gates Foundation (BMGF), the United States (USAID), the United Kingdom Department for International Development (DFID) and the Dutch Ministry of Foreign Affairs (Policy Cures, 2011) with the BMGF providing more than 50% of the funds.

Most PDPs manage a portfolio of products across a range of development phases, although frequently PDPs focus on a particular therapeutic category. It is still too early to credibly gauge PDP productivity in terms of final products, but we can note that despite their relative novelty, over 85% of products in development by 2008 for neglected diseases are associated with PDPs (GFHR, 2008) and PATH, FIND, MMV, DNDI, and the IOWH have all successfully launched new products in the past few years – a meningitis vaccine, TB diagnostic, pediatric formulations for an anti-malarial, a new ACT combination for malaria and a leishmaniasis drug respectively. All have a range of partnerships with MNCs and biotechnology companies; IFPMA’s partnership data base highlights close to 50 examples of MNCs working on product development with PDPs.
Table 5

Finance for Product Development Partnerships ($US, 2008)
Source: The George Institute (G-Finder Database)

<table>
<thead>
<tr>
<th>By Funding Source</th>
<th>By Disease</th>
<th>By Recipient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Source</td>
<td>Amount</td>
<td>Share</td>
</tr>
<tr>
<td>Philanthropic</td>
<td>$386,384,877</td>
<td>0.67</td>
</tr>
<tr>
<td>BMGF</td>
<td>$351,426,806</td>
<td>0.61</td>
</tr>
<tr>
<td>Other</td>
<td>$34,958,071</td>
<td>0.06</td>
</tr>
<tr>
<td>Governments</td>
<td>$188,068,613</td>
<td>0.32</td>
</tr>
<tr>
<td>US</td>
<td>$54,985,749</td>
<td>0.09</td>
</tr>
<tr>
<td>UK</td>
<td>$28,094,078</td>
<td>0.05</td>
</tr>
<tr>
<td>Netherlands</td>
<td>$19,807,167</td>
<td>0.03</td>
</tr>
<tr>
<td>Canada</td>
<td>$16,244,572</td>
<td>0.03</td>
</tr>
<tr>
<td>Spain</td>
<td>$13,116,473</td>
<td>0.02</td>
</tr>
<tr>
<td>Other</td>
<td>$55,820,574</td>
<td>0.10</td>
</tr>
<tr>
<td>Private Sector</td>
<td>$5,630,798</td>
<td>0.01</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$580,084,382</strong></td>
<td><strong>1.00</strong></td>
</tr>
</tbody>
</table>

9 BMGF=Bill and Melinda Gates Foundation
10 Multiple=Core funding of a multi-disease R&D organization, BPM=Bacterial Pneumonia & Meningitis, Delivery=Delivery Technologies and Devices
11 IAVI=International AIDS Vaccine Initiative, MMV=Medicines for Malaria Venture, WHO/TDR=World Health Organization: Special Programme for Research and Training in Tropical Diseases, iOWH=Institute for One World Health, DNDi=Drugs for Neglected Diseases initiative, IDRI=Infectious Disease Research Institute, EVI=European Vaccine Initiative
12 Private sector may also commit in-kind resources such as R&D facilities or personnel rather than direct investment into a PDP initiative. Additionally these figures are based on survey data. Both factors potentially bias the estimate.
Patent Pools
Patent pools are collections of patents contributed by IP holders for use by qualified users or other members in the pool. Members agree to use a set of patents as if pool members owned them jointly and to license them as a package to other firms or organizations. Patent pools have partial exclusivity, restricting use outside the pool but allowing use inside the pool. Pools reduce litigation risks and lower license fees and transactions costs for members and others qualified to access the patents.

While not patent pools in the technical sense – where members jointly own and work on patents together – a number of new initiatives designed to expand access to patents and “know-how” as a means to promote R&D and supply have adopted the title. One example is the Pool for Open Innovation, founded by GSK in 2009 and operated by BVGH. In this case, companies are encouraged to contribute patents and affiliated programs with the goal of making it easier for others to build on the companies’ research, successes and failures through their access to donated enabling technologies and data, including data on failures (Dentzer, 2009). The Pool for Open Innovation restricts licensing to efforts related to the 16 “neglected tropical diseases” as defined by the FDA (this list excludes HIV/AIDS) and any activity using the patents can only occur in the UN’s 49 Least Developed Countries.

In contrast, the UNITAID-supported effort, the Medicines Patent Pool targets HIV exclusively. It seeks to gain access to companies’ ARV therapy patents with the goal of increasing supply and of enabling the development of fixed dose combinations and pediatric formulations by other companies. (UNITAID, 2010). Participating IP contributors would be granted some royalty but how the value will be determined is not clear and likely to be highly contestable. The geographic scope of the initiative is also still under discussion – i.e. will companies be free to use the pool’s patents only for the patients in the low income countries or also for patients in middle income countries. As such the likelihood that such pools will generate significant entry is limited if rights by the originator to subsequent commercialization is restricted.

As pools are a relatively recent development (generally established since 2009), it is not clear the degree to which these initiatives will result in significant advances in either development or access to medicines. Whilst it can address the concern that MNCs may otherwise hang on to patents rights that they cannot commercially exploit, and also provides an outlet for new research by MNCs, product development costs still need to be met by someone.

4.3.2. Pull mechanisms
Whereas a push mechanism subsidizes research inputs, a pull mechanism rewards research output. A pull mechanism only provides payment if the developer meets a goal. The goal might be vaccine development, manufacturing, or access. Towse and Kettler (2005b) suggest that pull mechanisms for treatment of neglected diseases are successful when they are designed to: (1) motivate new research without
wasting resources; (2) specify which treatments are eligible; (3) be credible in eyes of developers; (4) handle follow-on drugs; and (5) ensure the products get used by patients.

**Advance market commitment**

Advanced market commitments are pull mechanisms in which donors encourage development of vaccines and other treatments by guaranteeing a specified price for up to a certain volume (Kremer and Glennerster, 2004; Berndt, Glennerster et al., 2007). Donors provide funding for the top up on the price of the product above what the buyer will pay in the long term, and specify the disease, product characteristics, and price in advance. By increasing prices, an advance market commitment can improve the value of the developing market relative to the developed market such that companies make a decision to enter the former as well as the latter.

To motivate companies to spend their own funds to develop products for a neglected disease, the AMC must be credible and the market offered must be sufficiently large (Levine, Kremer et al., 2005). Payment is made only when a product is developed, approved and the patients indicate a willingness to buy it; so the developer bears the technical and the demand risk. Donors cover the bulk of the price with the end user making a co-payment. The co-payment helps insure that a new product meets a market test. The price subsidy expires when the AMC guarantee is exhausted. After the funds expire, participating companies must supply the product or vaccine at low and sustainable prices, ideally at the level of the co-payment that the user is able to afford but more likely at a level that still requires some donor subsidies.

Pull mechanisms need to specify how second and later entrants are rewarded. The AMC handles this problem better than many pull mechanisms, because fast followers can capture some of the funds provided that either (i) entry occurs sufficiently soon after the first entrant that funds are still available or (ii) donors take the decision to reserve some funds to guarantee prices for later entrants with the explicit goal of bringing more than one company in to the market.

Towse and Kettler’s fifth criterion was that patients must get access to the new product. Again, the advance market commitment handles this concern better than many pull mechanisms because payment is based on utilization. After the AMC fund is exhausted, the participating suppliers commit to supply at the tail price. Less clear is whether the market created by the AMC (demand for the vaccine at the tail price) will serve as a sufficient draw to additional suppliers to enter once the AMC funds have been allocated.

The AMC has flaws that are characteristic of many pull mechanisms. If the payment is excessive, i.e. donors pay more in the form of a subsidy than they need to pull in the company, then resources are wasted, although higher prices are likely to get products to the market more quickly – something that can also be accomplished by a higher initial premium (Kremer et al., 2005). One way proposed to address this risk is for companies to bid on the reward they would want if they were successful in taking a pre-clinical candidate through human trials. The funder could construct an
AMC around the lowest bid, although arrangements would be needed to cover development failures and follow-on entry. While interesting in theory, it is unclear that such a scheme could be put in to practice.

Because clinical development takes many years, AMCs targeted at pulling forward early stage candidates will be announced well in advance of a successful product. It is challenging to specify this far in advance the target product profile and set a price. This time lag could favor developers and lead to the possibility of “agency capture”; if no company responds to the initial offer or respondents are struggling to make progress, donors will be under pressure to relax the definition of what qualifies or to increase the price (Farlow, Light et al., 2005). As the lag between design and approval increases, so too does the opportunity cost of capital and so the necessary price. Even advocates of the AMC, suggest it might be cheaper and more effective to start with push funding for early stage products and reserve pull mechanisms for later stage products (Farlow, Light et al., 2005).

In 2010 the first AMC was launched, to speed introduction of a pneumococcal vaccine to developing countries by encouraging companies to increase their global supply. The AMC requires eligible companies seeking the price premium to supply product to GAVI eligible countries at a price below the developed world price but higher than a local price countries could pay out of their own resources. Five countries and the BMGF committed U.S.$1.5 billion. Both Pfizer and GSK have a vaccine that the AMC Independent Adjudication Committee have deemed eligible for AMC funds and both have been introduced in a GAVI country, Pfizer’s in Nicaragua and GSK’s in Kenya.

Priority review vouchers
In 2007, the US passed in to law a priority review voucher (PRV) system where the developer of a treatment for a developing country neglected disease (such as malaria or leishmaniasis) receives a voucher for priority review from the Food and Drug Administration (FDA) to be used with a product of their choice or sold to another developer. The proposal for the voucher was published in 2006 (Ridley, Grabowski et al., 2006) and sponsored into U.S. law in 2007 by Senators Brownback and Brown.

Priority review means that the FDA aims to render a decision in 6 months. In contrast, the FDA aims to complete a standard review in about 10 months, and it often takes even longer. The median difference in recent years is about 7 months (Grabowski, Ridley et al., 2009) . Top selling treatments can yield billions in sales each year, so being approved months earlier can be worth hundreds of millions of dollars to the voucher holder (Ridley, Grabowski et al., 2006; Grabowski, Ridley et al., 2009). About half of the blockbuster drugs in the 1990s received a standard review, and thus could have benefited from a PRV. The voucher’s value derives from three factors: shifting sales earlier, longer effective patent life due to earlier entry , and competitive benefits from earlier entry vis-à-vis rivals. To redeem a voucher, the voucher holder must pay the FDA an additional user fee ($4,582,000 in 2011) and provide the agency with a one-year notice before redemption.
The PRV reduces two types of inefficiency. First, the voucher speeds approval of potential blockbuster therapies in the US, getting US patients access to these treatments more quickly. Second, the voucher motivates more treatments for neglected diseases, although it does not guarantee access to treatment in developing countries. Funding from governments or foundations might be needed to purchase treatments for poor people. If the voucher is too generous (the rewards far exceed the cost of the additional research), or it rewards research that would have been conducted anyway, value diminishes. Novartis won the first voucher in 2009 for US approval of its malaria therapy Coartem (artemether/lumefantrine), a product that was already on the market in other countries. How Novartis uses the voucher will signal to the market its potential value. A PRV scheme has also been proposed for Europe (Ridley and Calles Sanchez, 2010).

Patent extensions
Whereas the PRV speeds a product to market, an alternative reward would be to extend a product’s patent life. In the US, there currently exists a law that provides companies with a 6 month patent extension for developing pediatric formulations. Extending the patent of (say) a leishmaniasis drug would bring limited value to a company but offering a 6 month extension of a product of their choice, a transferable voucher, could have great value (Kettler, 2000). In contrast to the PRV, a transferable patent extension voucher would be applied to a product that has been on the market for many years, so there would be greater certainty about the value of extended exclusivity and it can be applied at the point when a product has reached peak sales, increasing its value.

A problem with transferable patent extensions, however, is that they delay access to generic drugs, keeping prices high, in effect taxing users of the drug receiving the patent extension to pay for neglected disease research. In the case of pediatric formulation patent extensions in the US, an FDA study determined that the additional cost of the policy was approximately $30 billion over 20 years with consumers footing 47% of the cost, generic firms losing 36% of the total and pharmacists (who typically charge more markup on generics) missing out on the remaining 17% (Kettler and Collins, 2002). Beneficiaries of the policy are clearly children who are prescribed (or would have been prescribed) the medicines on which additional studies were conducted. For the proposed transferable patent extension, developing countries would benefit while costs are borne by developed country consumers, generic firms and pharmacists. Patent extensions also have other problems familiar to pull mechanisms, in particular not ensuring that the neglected disease treatment that wins the reward actually reaches their targeted patients.

Prizes and “de-linking” the cost of R&D and the price of health products
One of the limitations of the PRV (and arguably the transferable patent extension idea) is that access agreements are not explicitly embedded in the legislation. The product developer is rewarded at the point of receiving FDA approval for a qualifying product but is not held accountable to a target product profile (is the product...
appropriate or affordable) or to participate in the product delivery process (does the product ever reach the intended patient?)

A recent review by Wilson and Palriwala (2010), found that various proposals have recently been put forward linked to the use of prizes as a pull incentive for product development, the most ambitious of which look to use the prize incentive as an alternative to patent protection. The prize reward is made contingent on the product developer making all the relevant IP available to competing manufacturers as a way to secure access (Love and Hubbard, 2007). Underlying this proposal is the idea that the cost of R&D should be “de-linked” from the price of the product. Rather than earn monopoly rents through patents, the prize would pay the company back for any costs incurred in a single payment and the generic companies would be free to manufacturer from the day the product is approved. Proponents of the Health Impact Fund (Banerjee, Hollis et al., 2010; Pogge and Hollis, 2008) put forward a different approach to achieve the desired innovation and health impact: a prize fund would again be used as the “draw” for innovation but in this case, the product is supplied at a generic price and the developer is not rewarded for the R&D element until it can demonstrate that the resulting product has health value for the intended patients, i.e. the rewards would be linked explicitly to health outcomes.

While the idea of de-linking R&D costs from the product price has attracted attention at the WHO and elsewhere, how feasible it is to implement in practice has yet to be demonstrated (WHO, 2008). It is unclear if companies would respond and invest their own resources (or investors theirs in the case of biotechnology companies) against the potential promise of some or all of a prize fund, whether there would be sufficient markets to attract multiple suppliers as a way to compete the prices down, whether the prize specifications can be sufficiently detailed as to steer companies to the “right” technologies (Wilson and Palriwala, 2010). The promoters of the Health Impact Fund recognize, for example, that they need to practical answers to the question of how health impact would be “demonstrated” in practice, and how their model would deal with follow-on products.

4.4 Combining, and trading-off between, push and pull mechanisms

At its simplest, push approaches involve payment in advance and pull approaches involve payment only when a product successfully reaches a pre-specified milestone, be that regulatory approval or a decision by payers to buy. The way push and pull mechanisms work as incentives could have important differences in the resulting development costs and success rates.

Push efforts should, at least in theory, have lower cost per input in cases where non-profits are directing the work, because they are able to negotiate preferential pricing for resources, staff, and contractors, as well as in-kind contributions from industry (Kettler, White et al., 2003; Moran, 2005).
Pull approaches, where companies are only rewarded for successes, means they are motivated to kill questionable projects early in an effort to avoid failures during the later, more expensive stages (Hsu and Schwartz, 2008). This could result in higher late stage success rates for pull driven work than push work though might also result in “overpruning” early, with some good but risky ideas being killed (a Type II error where companies underestimate the probability of success). With push approaches the developer might have an incentive to do the work even if it perceives a low chance of success, if it is getting paid for input. Under push, one might therefore expect to find more activity and larger portfolios of products, but lower success rates (Type 1 error where companies do not kill projects soon enough). PDPs are often evaluated on how much they have in the pipeline rather than how good the products are and whether they kept to their budget forecasts. This can motivate PDPs to keep projects alive and spend money. Rather than be rewarded for “under spending” during the term of a grant, i.e. organizing the business to save money until promising projects come along, the PDP risks losing the money in “use it or lose it” arrangements.

A better understanding of relationship between incentive tool and product developer’s behavior would in theory allow funders and tool designers to modify and combine tools so as to minimize costs and maximize success rates and efficiency. In reality, designers have limited flexibility because of legislative processes, contract regulations, lack of information, and the need to send clear signals to companies planning R&D investments. Nonetheless, there are modifications that could be made to improve the reward structures within push mechanisms to improve performance and outcomes and to combine push and pull so as to improve success rates.

The US Orphan Drug Act of 1983 and subsequent Japanese (1993) and European (2003) orphan drug policies, are examples of push-pull combinations – in this case combinations of tools designed to encourage R&D for drugs to treat orphan diseases, defined as diseases affecting a pre-specified “small” number of patients in the Act’s country. The US Orphan Drug Act combines a pull mechanism – seven years of marketing exclusivity upon FDA approval – with a number of push mechanisms – tax credits for up to half of their clinical testing expenses, tax credits for drugs requiring foreign testing when a sufficient testing population does not exist in the US, and modest grant and advisory support.

Most neglected diseases of the poor in developing countries also qualify for orphan status because of their low US prevalence, but there are limited US benefits from tackling them. Evidence suggests that the Orphan Drug Act works best for “rare but not too rare” diseases where companies can take full advantage of the exclusivity provision and offer high prices (Lichtenberg and Waldfogel, 2008; Yin, 2008). There are insufficient numbers of people to charge the high prices to for either “very rare” US based diseases or the neglected diseases of the global poor.
5. Conclusions

This paper details the approaches the pharmaceutical industry, governments and other stakeholders have employed (or advocated for) to A) improve access to existing global medicines and B) motivate new R&D for neglected disease drugs and vaccines. Incentives in both areas have changed substantially over the last decade, in part because of a positive change in the public policy and financing environment among donor governments, international agencies and major private foundations. Differential pricing, donations, and voluntary and compulsory licensing can increase access to “global” medicines among poor patients. With differential pricing MLIC markets are not necessarily unprofitable and will be a source of revenue growth for MNCs and regional companies. With the additional incentives from push and pull mechanisms, pharmaceutical firms have stronger incentives to develop medicines to treat neglected diseases. Not surprisingly many NGOs and academics remain critical of the industry’s performance and have proposed radical policy changes. Our view is that current and future initiatives should be based solidly on a mix of theory and empirical evidence; we have set out relevant theory and discussed existing evidence. As many programs aimed at improving R&D and access are relatively recent, future analyses of specific programs and initiatives will undoubtedly help us understand which policies and programs work well and which do not, and policy can be adjusted accordingly.
References


DCPP2 (2006). Disease Control Priority Project II.


http://www.who.int/intellectualproperty/submissions/MichealKremerKTW_CIPIH_submission_2.pdf


PF3 (2009) "Pharma Futures III." Volume, DOI:


Source: Authors’ calculations using 2004 World Health Organization data on standard disability-adjusted life years (3% discounting and age weights). Poor and lower-middle income countries classified according to World Bank definitions.